Can Teritusumab be used to treat multiple myeloma? How effective is it?

Teritolumab (Teclistamab) is an innovative immunotherapy drug, a bispecific antibody, mainly used to treat multiple myeloma (MM). It activates the patient's own T cells by simultaneously targeting two different molecules - BCMA (B cell maturation antigen) and CD3, allowing them to recognize and attack myeloma cells. BCMA is an important molecule highly expressed on the surface of multiple myeloma cells, making it an ideal target for the treatment of myeloma. CD3 is a receptor on the surface of T cells, and teritolumab binds BCMA< at the same time. /span> and CD3 activate the immune attack of T cells, thereby effectively killing multiple myeloma cells.

Teritusumab has shown encouraging clinical results in the treatment of multiple myeloma. Clinical studies have shown that teritusumab has a significant therapeutic effect on patients with multiple myeloma, especially those who are resistant to traditional treatment options (such as chemotherapy, interferon therapy, etc.). Teritusumab can effectively reduce the number of myeloma cells and significantly improve patients' quality of life and survival. Especially in patients with relapsed or refractory multiple myeloma, teritusumab has shown high efficacy, and some patients have even achieved complete remission.

According to clinical trial results, teritusumab has a higher objective response rate in the treatment of patients with relapsed or refractory multiple myeloma. After using this drug, many patients have significantly reduced levels of tumor markers such as M protein, and even complete remission in some patients. This efficacy makes teritusumab a potential drug for the treatment of multiple myeloma.

However, the therapeutic effect of teritusumab is not applicable to all patients, and individualized treatment is still very important. Clinical studies have also shown that the drug may be associated with some immune-related side effects, such as cytokine release syndrome (CRS) and neurological toxicity, which require close monitoring and appropriate management during treatment.

Overall, teritusumab, as an innovative immunotherapy drug, has proven its significant effect in the treatment of multiple myeloma, especially in relapsed or refractory cases, showing high therapeutic potential.

Reference materials:https://www.tecvayli.com/

xa0